Stephen Blakemore

Bioarray Genetics, Inc. develops a patent-pending chemotherapy response assay to help guide physicians in the selection of the most effective treatments. It also develops proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used. The company was founded by Marcia Fournier and Katherine J. Martin in 2009 and is headquartered in Farmington, CT.

Bioarray Genetics, Inc. develops a patent-pending chemotherapy response assay to help guide physicians in the selection of the most effective treatments. It also develops proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used. The company was founded by Marcia Fournier and Katherine J. Martin in 2009 and is headquartered in Farmington, CT.

Bioarray Genetics, Inc. develops a patent-pending chemotherapy response assay to help guide physicians in the selection of the most effective treatments. It also develops proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used. The company was founded by Marcia Fournier and Katherine J. Martin in 2009 and is headquartered in Farmington, CT.